Kura Oncology Inc. (KURA)
7.13
-0.01 (-0.14%)
At close: Mar 27, 2025, 3:59 PM
7.10
-0.44%
Pre-market: Mar 28, 2025, 07:00 AM EDT
-0.14% (1D)
| Bid | 7.08 |
| Market Cap | 576.19M |
| Revenue (ttm) | 49.94M |
| Net Income (ttm) | -161.24M |
| EPS (ttm) | -2.02 |
| PE Ratio (ttm) | -3.53 |
| Forward PE | -4.2 |
| Analyst | Buy |
| Ask | 7.8 |
| Volume | 350,303 |
| Avg. Volume (20D) | 1,501,486 |
| Open | 7.19 |
| Previous Close | 7.14 |
| Day's Range | 7.01 - 7.26 |
| 52-Week Range | 6.79 - 23.48 |
| Beta | 0.84 |
About KURA
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, includi...
Industry Biotechnology
Sector Healthcare
IPO Date Sep 16, 2015
Employees 192
Stock Exchange NASDAQ
Ticker Symbol KURA
Website https://kuraoncology.com
Analyst Forecast
According to 10 analyst ratings, the average rating for KURA stock is "Buy." The 12-month stock price forecast is $28, which is an increase of 292.43% from the latest price.
Stock Forecasts1 month ago
-2.54%
Kura Oncology shares are trading lower. The compan...
Unlock content with
Pro Subscription
1 month ago
+1.8%
Kura Oncology shares are trading lower. The company announced topline results from KOMET-001.
